Arbor Biotechnologies announced on May 8 that it entered into an agreement to acquire Serendipity Biosciences. The financial terms were not disclosed.
Serendipity Biosciences is a private biotechnology company focused on the discovery of unique gene editing technologies. Serendipity’s novel editing technologies were discovered in the lab of leading gene editing researcher and Arbor Biotechnologies co-founder, Feng Zhang, of the McGovern Institute for Brain Research at MIT and the Broad Institute of MIT and Harvard.
Arbor Biotechnologies is a next-generation gene editing biotechnology company based in Cambridge, Massachusetts. It is focused on discovering and developing potentially curative genomic medicines.
Serendipity’s assets, which include Fanzor-based, IsrB-based and additional undisclosed programmable editing technologies, complement and expand Arbor’s existing editing capabilities.
According to data captured in the LevinPro HC database, this acquisition represents the 66th Biotechnology transaction to be reported in 2024. Throughout 2023, there were 161 Biotechnology deals announced.
